Gallacher Capital Management LLC Purchases 317 Shares of Eli Lilly and Company $LLY

Gallacher Capital Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 66.2% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 796 shares of the company’s stock after acquiring an additional 317 shares during the period. Gallacher Capital Management LLC’s holdings in Eli Lilly and Company were worth $621,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in LLY. PNC Financial Services Group Inc. grew its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock worth $83,669,349,000 after buying an additional 50,002,551 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Eli Lilly and Company by 103,831.6% during the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company’s stock valued at $12,278,292,000 after buying an additional 14,852,076 shares during the period. Nuveen LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter worth $4,613,912,000. Vanguard Group Inc. increased its stake in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock worth $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Eli Lilly and Company by 15.9% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,084,880 shares of the company’s stock worth $5,469,527,000 after buying an additional 969,376 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on LLY shares. Deutsche Bank Aktiengesellschaft cut their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Leerink Partnrs lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Cantor Fitzgerald decreased their price objective on shares of Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a research note on Wednesday, August 13th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 price target (up previously from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday, July 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $941.35.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director J Erik Fyrwald acquired 1,565 shares of the stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the purchase, the chief executive officer directly owned 546,601 shares in the company, valued at approximately $352,431,926.77. This trade represents a 0.30% increase in their position. The disclosure for this purchase can be found here. Insiders acquired 4,514 shares of company stock worth $2,894,841 over the last 90 days. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Stock Down 0.2%

Shares of NYSE LLY opened at $754.90 on Monday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The stock has a market cap of $714.48 billion, a PE ratio of 49.34, a P/E/G ratio of 1.05 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a 50-day moving average of $741.03 and a 200 day moving average of $775.51.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 EPS. The business’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th were issued a dividend of $1.50 per share. The ex-dividend date was Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a yield of 0.8%. Eli Lilly and Company’s dividend payout ratio is 39.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.